Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This trial will evaluate whether the sequential administration of Cisplatin/Vinorelbine/Bevacizumab followed by Docetaxel/Gemcitabine/Bevacizumab versus the Cisplatin/Docetaxel/Bevacizumab combination as first line treatment offers a survival advantage in patients with locally advanced or metastatic NSCLC.
Critère d'inclusion
- non-small cell lung cancer